A Texas federal judge on Thursday awarded $24 million to a pharmaceutical service company that accused nursing home industry businesses of using its confidential information to set up a competitor, but affirmed a jury’s finding there had been no patent infringement.
A United Kingdom tribunal punted on GlaxoSmithKline PLC’s appeal over £37.6 million ($54 million) in antitrust fines from alleged “pay-for-delay” deals to postpone generic versions of blockbuster antidepressant Seroxat, sending the case to the Court of Justice of the European Union.
An Indiana federal jury on Friday slammed a Johnson & Johnson unit with a $35 million verdict in favor of a woman who claimed she was harmed by a pelvic mesh device, finding that the mesh implant was negligently designed and the company failed to warn of its risks.
The former CEO of a biotech research company slammed the U.S. Securities and Exchange Commission on Thursday in Maryland federal court, saying an amended complaint claiming he and other executives duped an auditor into allowing them to book $1.1 million in fake revenue still doesn’t allege any wrongdoing on his part and is a “misguided attempt of ‘guilt by association.’”
An antitrust trial set to kick off Monday in Boston will not include Federal Trade Commission studies on the importance of generic brands to competition, a federal judge ruled days before jury selection, in a win for the one drugmaker still fighting the pay-for-delay case.
Notorious former pharmaceutical executive Martin Shkreli was sentenced Friday to seven years in prison on his conviction for defrauding investors in his ailing hedge funds and conspiring to game biotech Retrophin Inc.'s stock price to pay off his debts.
A California federal judge Thursday indicated she might grant Genentech Inc. just a portion of the $5.8 million in attorneys’ fees the company requested after beating a patent infringement suit over its breast cancer drug, suggesting the case was “exceptional” for only part of the litigation.
Allegations that billionaire physician Patrick Soon-Shiong improperly tapped $47 million from biotech firm Precision Biologics Inc. survived a dismissal fight in Chancery Court late Thursday, with Delaware's chancellor cautioning that claims in the case need "pruning."
The Eleventh Circuit on Thursday affirmed an attorneys’ fee award to a Yale neurologist who beat back a defamation suit brought by a doctor he’d called a quack, ruling that the suit falls under the “exceptional case” standard for awarding attorneys’ fees under the Lanham Act.
BioXcel Therapeutics Inc., a company using artificial intelligence to develop drugs that fight cancer and neurological disorders, raised $60 million in an initial public offering that priced at the bottom of its forecasted range, marking the month’s first IPO although more are in the pipeline.
The Seventh Circuit on Thursday declined to revive an inadequate warning claim in a bellwether case in multidistrict litigation over alleged defects in Zimmer NexGen knee implants, saying that while the Wisconsin supreme court hasn’t addressed a particular doctrine, the panel predicted it would follow the lead of other courts.
Baker McKenzie said Thursday it is launching an office in Los Angeles after hiring five partners from Hogan Lovells US LLP, bringing on board attorneys steeped in experience in employment, life sciences, energy, product liability and commercial matters to bolster its West Coast offerings.
A senior U.S. Department of Justice official said the DOJ is ramping up its use of the False Claims Act to crack down on unnecessary prescriptions for opioid painkillers, as part of broader focus on fighting opioid abuse. Correction: An earlier version of the story listed Cox's speech as having taken place on Mar. 8. The error has been corrected.
California's attorney general has accused the National Cancer Coalition of painting a rosier-than-reality financial picture for potential donors by inflating the value of drug donations that it receives and distributes overseas, according to an unfair competition lawsuit filed in state court.
The Patent Trial and Appeal Board on Wednesday tore apart and then partly salvaged sleep apnea treatment patents owned by ResMed Corp. and Fisher & Paykel Healthcare Ltd. in nine challenges the two cross-filed.
The Federal Circuit on Thursday upheld a decision that Exergen Corp.'s forehead thermometer patents are not invalid for claiming laws of nature, though it found that only one of the two patents was infringed by Kaz USA Inc. and vacated a $15 million damages award.
The U.S. patent office insisted before an en banc panel of the Federal Circuit on Thursday that the agency was well within its rights in 2015 when it suddenly began making patent applicants cover all legal costs associated with challenges to patent denials in federal district court, upending 170 years of established practice.
Prevail Therapeutics Inc., a New York biotechnology company focused on fighting neurodegenerative diseases like Parkinson’s, on Thursday said it pocketed $75 million in its latest funding round thanks to investors including private equity and venture capital firm OrbiMed Advisors.
A Danvers, Massachusetts-based medical implant manufacturer has agreed to pay $3.1 million to resolve federal allegations claiming it promoted a line of heart pumps by doling out lavish free meals from Boston to Beverly Hills in violation of the False Claims Act, the U.S. attorney said Thursday.
Littler Mendelson PC has added a former Alexion Pharmaceuticals Inc. in-house attorney with experience in a variety of employment issues ranging from benefits to employee relations, the firm said in an announcement.
In "Justice and Empathy: Toward a Constitutional Ideal," the late Yale Law School professor Robert Burt makes a compelling case for the undeniable role of the courts in protecting the vulnerable and oppressed. But the question of how the judiciary might conform to Burt’s expectations raises practical problems, says U.S. Circuit Judge Allyson Duncan of the Fourth Circuit.
Two new policies from the U.S. Department of Justice, along with ongoing developments concerning the elements of scienter and materiality stemming from the landmark U.S. Supreme Court decision in Escobar, have the potential to significantly change the landscape of False Claims Act enforcement in the year ahead, say attorneys with Holland & Knight LLP.
In the hopes of piquing the interest of jurors and minimizing hardship requests, more and more judges are encouraging parties to make “mini-openings” prior to voir dire. You can use this as an opportunity to identify your worst jurors and get them removed from the panel — by previewing your case weaknesses and withholding your strengths, says Christina Marinakis of Litigation Insights.
Recent insurance decisions underscore the importance of understanding how directors and officers liability insurance applies in government investigations. Patriarch v. AXIS is particularly interesting because the insurer wanted to define "claim" more broadly than the policyholder, say Caroline Meneau and Brian Scarbrough of Jenner & Block LLP.
The U.S. associate attorney general recently issued a memo directing civil litigators in the U.S. Department of Justice to limit their use of governmental agency guidance documents in affirmative civil enforcement matters. Attorneys with Ropes & Gray LLP discuss issues that should be monitored over time in order to understand the memo's ultimate impact on civil health care enforcement matters.
As litigation funding becomes more widespread, greater complexity and variability in funding deals are to be expected. All claimants should consider certain key questions on the economics of single-case funding when considering or comparing funding terms, says Julia Gewolb of Bentham IMF.
The American public increasingly perceives that powerful people and institutions use their authority in selfish ways. And in the courtroom, jurors are homing in on where the power lies in a case story, and how that power is used. Those of us in litigation must heed the messages jurors are sending, says Melissa Gomez of MMG Jury Consulting LLC.
Given the operational and security risks involved, and the substantial digital asset values transacted, the rise of distributed ledger technology and smart contracts will create new opportunities and responsibilities for transactional lawyers, say attorneys with Potter Anderson Corroon LLP.
A witness who has been told what to do and what not to do will be ineffective at best. Instead, witnesses must be taught how to handle the process, and how to approach the answer to every question that they encounter. These are new skills, and they must be practiced in order to be learned, says Ric Dexter, an independent litigation consultant.
Law firms claim they create client teams to improve service. Clients aren’t fooled, describing these initiatives as “thinly veiled sales campaigns.” Until firms and client teams begin to apply a number of principles consistently, they will continue to fail and further erode clients’ trust, says legal industry coach Mike O’Horo.